IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
RMDL: Classification of Parkinson's disease by nature-inspired Algorithm
Antidiabetic activity (In vitro alpha amylase inhibitory) of ethanol extract of Carissa carandas Linn. roots.
Six sigma: an embellished exploration in the field of pharmaceutical industry
The effect of Sida acuta on bacterial enzymes in azoxymethane-induced experimental colon cancer
Premature ageing in children: a rare genetic disorder called progeria.
Stress, Depression & Gut Microbiota: The Gut-Brain Axis Regulation
Zinc oxide nanoparticles and antibiotics mediated combinatorial approach to enhance antibacterial potential
Quality of life and associated factors among students in Jambi Province, Indonesia
Novel method for simultaneous determination of spiramycin and metronidazole in pharmaceutical dosage form by UV-visible absorption spectrophotometry
The Influence of Physicians Social Capital on Patients Satisfaction
1234
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Potential link between Helicobacter pylori seropositivity and macrophage migration inhibitory factor in patients with myocardial infarction underwent primary percutaneous coronary intervention

Author: FEYAN ABDULLAH, RUQAYA MOHAMMED GHAREEB TAHER AL-BARZINJI
Abstract: Objective: To determine the possible link between helicobacter pylori (HP) seropositivity and macrophage migration inhibitory factor (MIF) level in myocardial infarction (MI) patients admitted for primary percutaneous coronary intervention (PPCI). Method: This case control study was carried out on 100 MI, 38 stable angina pectoris (SAP), and 38 subjects as control who admitted to surgical specialty hospital-cardiac centre in Erbil City, Iraq from January to December 2017. Levels of MIF and anti-HP IgG, IgA, and IgM were detected by enzyme linked immunosorbent assay (ELISA). Polymerase chain reaction (PCR) was done to detect HP 16SrRNA in those samples with IgM+ and/or IgG+IgA+. Results: Anti-Hp-IgG was positive in 68%, and 55.26% of MI, and SAP patients respectively. A higher proportion of HP seropositivity was observed in control group (84.21%). Molecular analysis showed no positive result for HP genomic material. MIF level was insignificantly differed between seropositive and seronegative MI patients (p>0.05). Seropositive MI group had higher MIF level compared to seropositive and negative control groups (p<0.05). Conclusion: Result of current study suggested that HP does not have direct role in MI elevated MIF, consequently demonstrated secondary contribution of HP in the development and progression of MI through low grade inflammatory response represented by insignificant elevation of MIF, and other inflammatory biomarkers (hsCRP, and fibrinogen).
Keyword: MIF, PPCI
DOI: https://doi.org/10.31838/ijpr/2019.11.02.109
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free